Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,284 across all filing types
Latest filing 2025-04-02 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
立信会计师事务所（特殊普通合伙）关于瑞普生物股份有限公司2024年度募集资金存放与使用情况专项报告的鉴证报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the annual status of the company's raised funds (募集资金) for the year 2024, including the storage, management, and usage of these funds. It includes an auditor's assurance report (鉴证报告) on the special report of the raised funds usage, referencing regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document contains extensive financial data, tables, and explanations about the raised funds, their investment projects, usage progress, and compliance with regulatory requirements. It is not a general annual report (10-K), nor an earnings release or management discussion. It is a specialized report focused on the raised capital funds usage and compliance, which aligns with the category of Capital/Financing Update (CAP). The document is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the best fitting classification is CAP with high confidence.
2025-04-02 Chinese
关于举办2024年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2024 annual performance briefing (业绩说明会) by 瑞普生物股份有限公司. It references that the full 2024 annual report has already been disclosed on April 3, 2025, on official websites. The document invites investors to participate in a remote text-based Q&A session on April 21, 2025, with company executives. The content is focused on announcing the event and inviting participation rather than providing the actual report or detailed financial data. The document length is short (934 characters) and it primarily serves as a notice for an upcoming investor presentation or briefing session. According to the classification rules, such announcements about meetings or presentations are best classified as Investor Presentation (IP) if they contain detailed presentation content, or as Report Publication Announcement (RPA) if they announce the release of a report. However, this document is specifically about an earnings explanation meeting (业绩说明会), which aligns with an Investor Presentation (IP) since it is a detailed presentation for investors focusing on financials and company performance. Therefore, the best fit is Investor Presentation (IP).
2025-04-02 Chinese
2024年年度审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an audit report and financial statements for the fiscal year 2024, covering the period from January 1, 2024 to December 31, 2024. It includes an auditor's opinion, detailed audit procedures, key audit matters, management and governance responsibilities, and comprehensive financial statements such as consolidated and parent company balance sheets, income statements, and cash flow statements. The presence of an auditor's report with registration numbers, detailed financial data, and notes confirms this is a full audit report with financial statements, not just an announcement or certification. The document length is substantial (15,000 characters), and it contains actual financial data and analysis. Therefore, it fits the category of an Audit Report / Information (AR) rather than a full Annual Report (10-K) which would typically include more narrative sections beyond the audit and financial statements, or other categories like Regulatory Filings or Report Publication Announcements. Hence, the classification is AR with high confidence. FY 2024
2025-04-02 Chinese
关于召开2024年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of 瑞普生物股份有限公司. It includes information about the meeting date, voting procedures (both in-person and online), agenda items to be discussed and voted on, registration details, and attachments such as proxy forms and shareholder registration forms. The document does not contain financial statements or detailed financial analysis but rather logistical and procedural information related to the AGM. It is not the annual report itself, nor an earnings release or other financial report. It is clearly a notice and materials related to the AGM, which fits the definition of AGM Information (AGM-R). The document length (4815 characters) and content confirm it is the meeting notice and related information, not a report publication announcement or regulatory filing. Therefore, the correct classification is AGM Information (AGM-R).
2025-04-02 Chinese
董事会对独董独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board of directors regarding the independence of the company's independent directors, referencing regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange guidelines. It does not contain financial data, audit results, or report publication announcements. It is a governance-related statement about board members' independence, which fits best under Governance Information (CGR). The document length is short and focused on governance compliance rather than financial or operational reporting.
2025-04-02 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 22nd meeting of the 5th Board of Directors of 瑞普生物股份有限公司 (Ruipu Bio Co., Ltd.) held on April 1, 2025. It includes approvals of various reports and proposals related to the 2024 fiscal year, such as the 2024 Board Work Report, 2024 Financial Final Report, 2024 Audited Financial Report, 2024 Annual Report and Summary, 2024 Profit Distribution Plan, 2024 Fundraising Use Report, 2024 Internal Control Self-Evaluation Report, 2024 ESG Report, and others. The document repeatedly states that these reports and proposals will be submitted to the 2024 Annual General Meeting (AGM) for approval. It also includes voting results and procedural details of the board meeting. The document is not the reports themselves but a formal announcement of the board meeting resolutions and the intention to submit these matters to the AGM. The document length is 7684 characters, which is substantial but the content is clearly a board meeting resolution announcement rather than the full annual report or financial statements. Therefore, the document fits best into the category of Board/Management Information (MANG), as it announces board decisions and management resolutions related to the company’s governance and reporting, rather than being the actual reports or financial statements themselves.
2025-04-02 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.